Pricing Log in Create free account
Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue
−1.90%
EPS
−47.2%
Free cash flow
−30.3%
Total debt
−0.43%

Quarter to September 2026, against a year earlier

42.12 0.34 +0.81%
Market cap
$48.7B
P/E
92.6×
Fwd P/E
30.7×
Dividend yield
—
F-score
8/9
Altman Z
0.79
Beneish M
−2.35
Dividend safety
52/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. 8-K filed Nov 8, 2023

Period ended Nov 8, 2023 · Filed · accepted 7:01 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov